Kidney Tumor Study München Klinik Bogenhause

Conditions: C64
Malignant neoplasm of kidney, except renal pelvis

Registration Number: DRKS00034124

Lead Sponsor: Klinik für Urologie, München Klinik Bogenhausen gGmbH

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 300

Inclusion Criteria

Histopathological evidence of renal cell carcinoma
- Availability of the image data from the cross-sectional imaging (CT or MRI; CD, USB, internal clinic data storage)
- Primary operation in the Department of Urology at the Munich Clinic gGmbH
- Ability to give consent to participate in the study (for legally cared for patients by the legal carer)

Exclusion Criteria

- Known, hereditary or acquired bleeding tendency (participation is possible if there is a medication-related bleeding tendency; the medication will be adjusted according to the recommendation of the initially ordering doctor or the responsible department in the hospital)
- Anatomical anomalies such as severe scoliosis or short stature that prevent a standardized approach
- Patients with urothelial carcinoma of the upper urinary tract (e.g. renal pelvic carcinoma)

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of complications<br><br>Rate of complications = grade III according to the Clavien-Dindo classification after renal tumor surgery depending on the surgical procedure used (open, laparoscopic and robotically assisted nephrectomies and partial nephrectomies/renal tumor enucleations for renal cell carcinoma) as well as depending on the patient's R.E.N.A.L. score. All data collected within the Munich Clinic such as laboratory results, radiological reports and surgical reports can be found in SAP®. The medical and nursing documentation is paper-based in the patient file. In the case of paper-based documentation, it is digitized and stored in SAP® after discharge of the patient. The endpoints are evaluated and documented either directly when a complication occurs during the inpatient stay by the doctor or a study nurse. After discharge, the study nurse carries out the annual evaluation and update of occuring complications.

Secondary Outcome Measures

Name	Time	Method
Survival (overall survival, progression-free survival, recurrence-free survival)<br><br>The overall duration of the study is intended to be indefinite, but at least five years. An annual evaluation will be carried out.